Renaissance Technologies LLC Trims Stock Holdings in Karyopharm Therapeutics Inc. (NASDAQ:KPTI)

Renaissance Technologies LLC reduced its position in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) by 16.6% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 756,227 shares of the company’s stock after selling 150,573 shares during the quarter. Renaissance Technologies LLC owned about 0.61% of Karyopharm Therapeutics worth $656,000 at the end of the most recent reporting period.

Separately, Acadian Asset Management LLC acquired a new stake in Karyopharm Therapeutics during the 2nd quarter worth approximately $167,000. 66.44% of the stock is currently owned by hedge funds and other institutional investors.

Karyopharm Therapeutics Stock Down 3.1 %

Shares of NASDAQ:KPTI opened at $0.84 on Wednesday. The company has a market capitalization of $105.05 million, a price-to-earnings ratio of -0.66 and a beta of 0.20. The company has a 50 day moving average of $0.79 and a two-hundred day moving average of $0.98. Karyopharm Therapeutics Inc. has a 52-week low of $0.62 and a 52-week high of $1.95.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its earnings results on Tuesday, August 6th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.09. The business had revenue of $42.79 million during the quarter, compared to analyst estimates of $36.07 million. On average, equities analysts anticipate that Karyopharm Therapeutics Inc. will post -0.93 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the stock. Royal Bank of Canada reissued an “outperform” rating and set a $3.00 price target on shares of Karyopharm Therapeutics in a report on Wednesday, August 7th. StockNews.com raised Karyopharm Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. Robert W. Baird reduced their price target on Karyopharm Therapeutics from $8.00 to $5.00 and set an “outperform” rating for the company in a report on Wednesday, August 7th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $7.00 price objective on shares of Karyopharm Therapeutics in a report on Wednesday, August 7th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $4.80.

Karyopharm Therapeutics Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).